助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   抗阿尔茨海默病 的翻译结果: 查询用时:0.02秒
图标索引 在分类学科中查询
所有学科
精神病学
中药学
更多类别查询

图标索引 历史查询
 

抗阿尔茨海默病     
相关语句
  anti-alzheimer disease
     Construction of anti-Alzheimer disease recombinant plasmids
     抗阿尔茨海默病重组真核表达载体的构建
短句来源
  anti-alzheimer ' s disease
     The cloning and expression of an anti-Alzheimer's disease neuroprotective peptide gene humanin
     抗阿尔茨海默病神经保护肽humanin基因的克隆与表达
短句来源
     Simultaneous Analysis of Six Effective Components in the Anti-Alzheimer's Disease Effective Component Group of Xiao-Xu-Ming Decoction
     中药复方小续命汤抗阿尔茨海默病有效成分组中6种有效成分的同时测定
短句来源
  anti alzheimer disease
     Objective:To construct anti Alzheimer disease recombinant plasmids by fusing N terminal epitope gene of the amyloid β peptide(Aβ) with mice IgG he avy chain gene in 4 ways.
     目的 :将淀粉样蛋白 N端的抗原表位基因以 4种不同的组合与小鼠 Ig G重链区基因融合 ,构建抗阿尔茨海默病的重组质粒。
短句来源
     Conclusion: Four recombinant plasmid candidates of anti Alzheimer disease have been successfully constructed, and this may provide a basis for the prevention and treatment of the disease.
     结论 :成功构建了抗阿尔茨海默病的 4种表位基因 - Ig G重链区融合表达的重组质粒 ,为探索防治阿尔茨海默病打下基础
短句来源
     BACKGROUND:As the second anti Alzheimer disease drug approved by Food and Drug Administration(FDA),donepezil (Aricept) has been applied in European and American market. According to the regulation of Health Ministry of China,it needs conducting clinical trial of multiple center nationwide in order to come into Chinese market.
     背景:多奈哌齐(商品名安理申)作为FDA批准的第二个抗阿尔茨海默病药物在欧美等国已上市应用,卫生部规定,在中国上市前需做全国范围内多中心联合临床观察试验。
短句来源
  anti alzheimer ′ s disease
     AIM To study the action of melatonin on the expression of CD45 in BV 2 microglia and the influence of melatonin on BV 2 microglia activation so as to explore the antiaging and anti Alzheimer′s disease mechanisms of melatonin.
     目的 研究褪黑素对低氧激活的小胶质细胞CD4 5表达的影响 ,以探讨褪黑素的抗衰老和抗阿尔茨海默病的作用机制。
短句来源

 

查询“抗阿尔茨海默病”译词为其他词的双语例句

     

    查询“抗阿尔茨海默病”译词为用户自定义的双语例句

        我想查看译文中含有:的双语例句
    例句
    没有找到相关例句


    Objective:To construct anti Alzheimer disease recombinant plasmids by fusing N terminal epitope gene of the amyloid β peptide(Aβ) with mice IgG he avy chain gene in 4 ways. Methods: Mice IgG heavy chain cDNAs, prepared from mice spleen tissue using RT PCR were used as template DNA for PCR of the sense primers containing a flexible adaptor and epitope sequences at the ir 5′ ends. The resultant genes were then cloned into pVAX vector. All junctio n area of the recombinant DNAs were confirmed by endonuclease...

    Objective:To construct anti Alzheimer disease recombinant plasmids by fusing N terminal epitope gene of the amyloid β peptide(Aβ) with mice IgG he avy chain gene in 4 ways. Methods: Mice IgG heavy chain cDNAs, prepared from mice spleen tissue using RT PCR were used as template DNA for PCR of the sense primers containing a flexible adaptor and epitope sequences at the ir 5′ ends. The resultant genes were then cloned into pVAX vector. All junctio n area of the recombinant DNAs were confirmed by endonuclease digestion and sequ encing. Results: Endonuclease digestion of the recombinant plasm ids indicated that all the 4 fusion genes (999,1 020,1 005,1 026 bp) were insert ed into pVAX vectors with correct directions. Sequence analyses suggested that t he IgG heavy chain and the epitopes sequences were identical to those published in GenBank. Conclusion: Four recombinant plasmid candidates of anti Alzheimer disease have been successfully constructed, and this may provide a basis for the prevention and treatment of the disease.

    目的 :将淀粉样蛋白 N端的抗原表位基因以 4种不同的组合与小鼠 Ig G重链区基因融合 ,构建抗阿尔茨海默病的重组质粒。方法 :通过 RT- PCR技术从小鼠脾组织中克隆 Ig G重链区 c DNA,将柔性接头与抗原表位基因序列设计在 5′端引物中 ,然后以克隆出的小鼠 Ig G重链区 c DNA为模板 ,用 PCR法克隆出由柔性接头将抗原表位和 Ig G重链区基因融合在一起的序列 ,并插入到 p VAX质粒载体中。结果 :扩增出来的 4种不同组合的抗原表位基因和 Ig G重链区基因融合序列大小分别为 999、1 0 2 0、1 0 0 5、1 0 2 6 bp,均与 Gen Bank上登录的相符 ;p VAX重组质粒酶切结果表明融合基因正确地插入到 p VAX载体中 ,全自动测序亦显示抗原表位基因和 Ig G重链区基因为所需基因 ,接头序列也完全正确。结论 :成功构建了抗阿尔茨海默病的 4种表位基因 - Ig G重链区融合表达的重组质粒 ,为探索防治阿尔茨海默病打下基础

    AIM To study the action of melatonin on the expression of CD45 in BV 2 microglia and the influence of melatonin on BV 2 microglia activation so as to explore the antiaging and anti Alzheimer′s disease mechanisms of melatonin. METHODS Hypoxia in cultured BV 2 microglia was induced by sodium dithionite 2.0 mmol·L -1 for 48 h. The expression of CD45 on the BV 2 microglia surface was measured by flow cytometry, the morphological changes of BV 2 microglia were photographed with the phase contrast microscope....

    AIM To study the action of melatonin on the expression of CD45 in BV 2 microglia and the influence of melatonin on BV 2 microglia activation so as to explore the antiaging and anti Alzheimer′s disease mechanisms of melatonin. METHODS Hypoxia in cultured BV 2 microglia was induced by sodium dithionite 2.0 mmol·L -1 for 48 h. The expression of CD45 on the BV 2 microglia surface was measured by flow cytometry, the morphological changes of BV 2 microglia were photographed with the phase contrast microscope. BV 2 microglia were exposed to 20 mg·L -1 lipopolysaccharides 5 min after treated with 0.01, 0.1, 1.0 μmol·L -1 of melatonin, then incubated for 12 h. NO level in the medium was determined by Griess reagent. RESULTS The fluorescent intensity produced by CD45 expression in BV 2 microglia increased from 0.80±0.73 (normal control) to 23.9±14.2 (hypoxia model). Melatonin (0.01, 0.1, 1.0 μmol·L -1 ) significantly inhibited the elevation of CD45 expression in microglia in a concentration dependent manner, the fluorescent intensity is 9.3±3.1, 7.0±4.85 and 5.4±1.0, respectively. Melatonin could inhibit the morphological change of BV 2 microglia to amebocyte. But melatonin did not antagonize the increase in NO level in the medium induced by lipopolysaccharide. CONCLUSION Melatonin inhibiting the microglia activation by its anti oxidative action might be an important theoretical basis of anti inflammation and anti Alzheimer′s disease effects.

    目的 研究褪黑素对低氧激活的小胶质细胞CD4 5表达的影响 ,以探讨褪黑素的抗衰老和抗阿尔茨海默病的作用机制。方法 体外培养BV 2小胶质细胞 ,用终浓度为 2 .0mmol·L- 1的连二亚硫酸钠作用 4 8h ,造成慢性低氧模型 ,药物处理组在低氧的同时给予褪黑素。相差显微镜下观察小胶细质胞形态学变化 ,流式细胞术测定缺氧状态下BV 2小胶质细胞表面CD4 5的表达 ;体外培养BV 2小胶质细胞用终浓度为 0 .0 1,0 .1,1.0 μmol·L- 1的褪黑素作用5min ,加入 2 0mg·L- 1的脂多糖 37℃孵育 12h ,Griess试剂法检测培养上清中NO的含量。结果 连二亚硫酸钠引起的低氧可明显增加BV 2小胶质细胞CD4 5的表达 ,荧光强度增至 2 3.9± 14 .2 (对照组为0 .80± 0 .73) ,低氧也可使小胶质细胞的形态发生阿米巴样变 ,而 0 .0 1,0 .1,1.0 μmol·L- 1的褪黑素可剂量依赖性地减少低氧诱导的CD4 5表达 ,抑制由低氧引起的小胶质细胞的阿米巴样变。但褪黑素对脂多糖诱导的BV 2小胶质细胞培养液中NO的升高无明显抑制作用。...

    目的 研究褪黑素对低氧激活的小胶质细胞CD4 5表达的影响 ,以探讨褪黑素的抗衰老和抗阿尔茨海默病的作用机制。方法 体外培养BV 2小胶质细胞 ,用终浓度为 2 .0mmol·L- 1的连二亚硫酸钠作用 4 8h ,造成慢性低氧模型 ,药物处理组在低氧的同时给予褪黑素。相差显微镜下观察小胶细质胞形态学变化 ,流式细胞术测定缺氧状态下BV 2小胶质细胞表面CD4 5的表达 ;体外培养BV 2小胶质细胞用终浓度为 0 .0 1,0 .1,1.0 μmol·L- 1的褪黑素作用5min ,加入 2 0mg·L- 1的脂多糖 37℃孵育 12h ,Griess试剂法检测培养上清中NO的含量。结果 连二亚硫酸钠引起的低氧可明显增加BV 2小胶质细胞CD4 5的表达 ,荧光强度增至 2 3.9± 14 .2 (对照组为0 .80± 0 .73) ,低氧也可使小胶质细胞的形态发生阿米巴样变 ,而 0 .0 1,0 .1,1.0 μmol·L- 1的褪黑素可剂量依赖性地减少低氧诱导的CD4 5表达 ,抑制由低氧引起的小胶质细胞的阿米巴样变。但褪黑素对脂多糖诱导的BV 2小胶质细胞培养液中NO的升高无明显抑制作用。结论 褪黑素抑制小胶质细胞的激活与其抗氧化作用密切相关 ,可能是其抗炎和防治阿尔茨海默病作用的重要理论基础

    BACKGROUND:As the second anti Alzheimer disease drug approved by Food and Drug Administration(FDA),donepezil (Aricept) has been applied in European and American market.According to the regulation of Health Ministry of China,it needs conducting clinical trial of multiple center nationwide in order to come into Chinese market. OBJECTIVE:To evaluate the efficiency and safety of donepezil on treating mild and moderate Alzheimer disease(AD). DESIGN:Randomized,single blind and placebo control prospective study...

    BACKGROUND:As the second anti Alzheimer disease drug approved by Food and Drug Administration(FDA),donepezil (Aricept) has been applied in European and American market.According to the regulation of Health Ministry of China,it needs conducting clinical trial of multiple center nationwide in order to come into Chinese market. OBJECTIVE:To evaluate the efficiency and safety of donepezil on treating mild and moderate Alzheimer disease(AD). DESIGN:Randomized,single blind and placebo control prospective study based on patients. SETTING:Neurological Department of Peking Hospital and Neurological Department of the 301 Hospital of Chinese PLA,and ect. PARTICIPANTS:Totally 188 patients with mild and moderate AD[with mini mental state examination(MMSE) score of 10 to 24 points] from 15 big hospitals of Beijng,Shanghai and Guangzhou were conducted 12 weeks' clinical trial,among which 89 cases were of single blind and placebo control study while 99 cases were of self controlled study.All the cases met the AD diagnostic standard of clinical neurology,linguistic dysfunction and stroke(NINCDS ADRDA) and the 4th edition of Statistic Manual (DSM IVR). INTERVENTIONS:Donepezil (5 mg/tablet,ip,5 mg/time) or placebo with same color,shape,flavor and size with donepezil (ip, 1 tablet/time) was taken orally for 12 consecutive weeks. MAIN OUTCOME MEASURES:MMSE,clinical dementia rating scale(CDR),activities of daily life scale(ADL),biochemical parameters,electrocardiograph(ECG) and chest x ray were conducted once every 4 weeks before and after treatment. RESULTS: The random,single blind and placebo control study showed that the score of MMSE,CDR and ADL was greatly improved in donepezil group after 12 weeks' treatment when comparing with placebo group(P< 0.01,0.05,0.01).Self controlled study showed that the score of MMSE,CRD and ADL in donepezil group after 12 weeks' treatment increased 3.5, 0.6 and 7.1 points respectively compared with those before treatment(P< 0.01,0.05,0.01).The score of MMSE was already improved in the 4th week of treatment. Among the 145 patients who took donepezil,7 cases(4.8%) experienced side effect of mild cholinergic excitability.In the placebo group,2 of the 43 cases appeared dizziness and nausea.There was no difference between two groups(P >0.05). CONCLUSION:Donepezil can effectively treat mild and moderate AD patients and improve their cognitive functions,dementia level and daily living abilities with good tolerance and high safety.

    背景:多奈哌齐(商品名安理申)作为FDA批准的第二个抗阿尔茨海默病药物在欧美等国已上市应用,卫生部规定,在中国上市前需做全国范围内多中心联合临床观察试验。目的:评价多奈哌齐治疗轻、中度阿尔茨海默病的有效性及安全性。设计:以患者为研究对象,随机、单盲、安慰剂对照的前瞻性研究。单位:北京医院的神经内科和解放军第三○一医院的神经内科。对象:1998/2000对北京、上海、广州15家大型综合医院的188例轻、中度阿尔茨海默病(简易智能状态量表10~24分)患者进行了12周临床试验,其中89例为单盲、安慰剂对照研究,99例为自身对照研究,所有阿尔茨海默病患者均符合国立神经病学、语言功能障碍和中风研究所(NINCDS-ADRDA)中的可能阿尔茨海默病标准及诊断与统计手册第4次修订版(DSM-IVR)中的阿尔茨海默病诊断标准。干预:给予多奈哌齐(口服,5mg/片,1次/d,5mg/次)或颜色、形状、味道、大小与多奈哌齐相同的安慰剂(口服,1次/d,1片/次),连续应用12周。主要观察指标:用药前和用药后每4周检查1次简易智能状态量表、临床痴呆程度量表、日常生活自理量表和实验室生化指标、心电图及胸片。结果:随机、...

    背景:多奈哌齐(商品名安理申)作为FDA批准的第二个抗阿尔茨海默病药物在欧美等国已上市应用,卫生部规定,在中国上市前需做全国范围内多中心联合临床观察试验。目的:评价多奈哌齐治疗轻、中度阿尔茨海默病的有效性及安全性。设计:以患者为研究对象,随机、单盲、安慰剂对照的前瞻性研究。单位:北京医院的神经内科和解放军第三○一医院的神经内科。对象:1998/2000对北京、上海、广州15家大型综合医院的188例轻、中度阿尔茨海默病(简易智能状态量表10~24分)患者进行了12周临床试验,其中89例为单盲、安慰剂对照研究,99例为自身对照研究,所有阿尔茨海默病患者均符合国立神经病学、语言功能障碍和中风研究所(NINCDS-ADRDA)中的可能阿尔茨海默病标准及诊断与统计手册第4次修订版(DSM-IVR)中的阿尔茨海默病诊断标准。干预:给予多奈哌齐(口服,5mg/片,1次/d,5mg/次)或颜色、形状、味道、大小与多奈哌齐相同的安慰剂(口服,1次/d,1片/次),连续应用12周。主要观察指标:用药前和用药后每4周检查1次简易智能状态量表、临床痴呆程度量表、日常生活自理量表和实验室生化指标、心电图及胸片。结果:随机、单盲、安慰剂对照组研究结果表明,5mg/d多奈哌齐治疗12周时,多奈哌齐组较安慰剂组简易智能状态量表,临床痴呆程度量表及

     
    << 更多相关文摘    
    图标索引 相关查询

     


     
    CNKI小工具
    在英文学术搜索中查有关抗阿尔茨海默病的内容
    在知识搜索中查有关抗阿尔茨海默病的内容
    在数字搜索中查有关抗阿尔茨海默病的内容
    在概念知识元中查有关抗阿尔茨海默病的内容
    在学术趋势中查有关抗阿尔茨海默病的内容
     
     

    CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
    版权图标  2008 CNKI-中国知网
    京ICP证040431号 互联网出版许可证 新出网证(京)字008号
    北京市公安局海淀分局 备案号:110 1081725
    版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社